PMC:7205724 / 10726-11458
Annnotations
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
---|---|---|---|---|---|
353 | 392-395 | Gene | denotes | CRP | Gene:1401 |
354 | 234-242 | Species | denotes | patients | Tax:9606 |
355 | 318-326 | Species | denotes | patients | Tax:9606 |
356 | 457-465 | Species | denotes | patients | Tax:9606 |
357 | 475-484 | Species | denotes | SARS-CoV2 | Tax:2697049 |
358 | 547-556 | Species | denotes | SARS-CoV2 | Tax:2697049 |
359 | 255-263 | Disease | denotes | COVID-19 | MESH:C000657245 |
LitCovid-PD-FMA-UBERON
Id | Subject | Object | Predicate | Lexical cue | fma_id |
---|---|---|---|---|---|
T75 | 83-89 | Body_part | denotes | plasma | http://purl.org/sig/ont/fma/fma62970 |
T76 | 103-111 | Body_part | denotes | antibody | http://purl.org/sig/ont/fma/fma62871 |
T77 | 357-367 | Body_part | denotes | lymphocyte | http://purl.org/sig/ont/fma/fma62863 |
T78 | 435-441 | Body_part | denotes | plasma | http://purl.org/sig/ont/fma/fma62970 |
T79 | 485-488 | Body_part | denotes | RNA | http://purl.org/sig/ont/fma/fma67095 |
T80 | 533-539 | Body_part | denotes | plasma | http://purl.org/sig/ont/fma/fma62970 |
T81 | 619-625 | Body_part | denotes | plasma | http://purl.org/sig/ont/fma/fma62970 |
T82 | 725-731 | Body_part | denotes | plasma | http://purl.org/sig/ont/fma/fma62970 |
LitCovid-PD-MONDO
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T67 | 255-263 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T68 | 475-479 | Disease | denotes | SARS | http://purl.obolibrary.org/obo/MONDO_0005091 |
T69 | 547-551 | Disease | denotes | SARS | http://purl.obolibrary.org/obo/MONDO_0005091 |
LitCovid-PD-CLO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T113 | 0-1 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | A |
T114 | 15-17 | http://purl.obolibrary.org/obo/CLO_0053733 | denotes | 11 |
T115 | 28-31 | http://purl.obolibrary.org/obo/CLO_0051582 | denotes | has |
T116 | 83-89 | http://purl.obolibrary.org/obo/UBERON_0001969 | denotes | plasma |
T117 | 230-233 | http://purl.obolibrary.org/obo/CLO_0050884 | denotes | ten |
T118 | 314-317 | http://purl.obolibrary.org/obo/CLO_0050884 | denotes | ten |
T119 | 378-379 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T120 | 435-441 | http://purl.obolibrary.org/obo/UBERON_0001969 | denotes | plasma |
T121 | 533-539 | http://purl.obolibrary.org/obo/UBERON_0001969 | denotes | plasma |
T122 | 619-625 | http://purl.obolibrary.org/obo/UBERON_0001969 | denotes | plasma |
T123 | 725-731 | http://purl.obolibrary.org/obo/UBERON_0001969 | denotes | plasma |
LitCovid-PD-CHEBI
Id | Subject | Object | Predicate | Lexical cue | chebi_id |
---|---|---|---|---|---|
T121 | 159-176 | Chemical | denotes | anti-viral agents | http://purl.obolibrary.org/obo/CHEBI_22587 |
LitCovid-sample-MedDRA
Id | Subject | Object | Predicate | Lexical cue | meddra_id |
---|---|---|---|---|---|
T6 | 32-44 | http://purl.bioontology.org/ontology/MEDDRA/10022891 | denotes | investigated | http://purl.bioontology.org/ontology/MEDDRA/10062026 |
T7 | 357-373 | http://purl.bioontology.org/ontology/MEDDRA/10022891 | denotes | lymphocyte count | http://purl.bioontology.org/ontology/MEDDRA/10025251 |
LitCovid-sample-CHEBI
Id | Subject | Object | Predicate | Lexical cue | chebi_id |
---|---|---|---|---|---|
T82 | 485-488 | Chemical | denotes | RNA | http://purl.obolibrary.org/obo/CHEBI_33697 |
LitCovid-sample-PD-NCBITaxon
Id | Subject | Object | Predicate | Lexical cue | ncbi_taxonomy_id |
---|---|---|---|---|---|
T82 | 255-263 | Species | denotes | COVID-19 | NCBItxid:2697049 |
T83 | 475-484 | Species | denotes | SARS-CoV2 | NCBItxid:2697049 |
T84 | 547-556 | Species | denotes | SARS-CoV2 | NCBItxid:2697049 |
LitCovid-sample-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T92 | 0-264 | Sentence | denotes | A pilot study [11] recently has investigated the safety and effect of convalescent plasma that contain antibody levels higher than 1:640 combined with regular anti-viral agents and standard supportive care on clinical outcomes of ten patients with severe COVID-19. |
T93 | 265-396 | Sentence | denotes | The study showed clinical improvement of all the ten patients accompanied by an increase in lymphocyte count and a decrease in CRP. |
T94 | 397-566 | Sentence | denotes | Following transfusion of convalescent plasma, all the seven patients who were SARS-CoV2 RNA positive before transfusion of convalescent plasma turned SARS-CoV2 negative. |
T95 | 567-732 | Sentence | denotes | There were no control groups receiving convalescent plasma alone or standard therapy without convalescent therapy to evaluate the main effect of convalescent plasma. |
LitCovid-sample-Pubtator
Id | Subject | Object | Predicate | Lexical cue | pubann:denotes |
---|---|---|---|---|---|
354 | 234-242 | Species | denotes | patients | Tax:9606 |
359 | 255-263 | Disease | denotes | COVID-19 | MESH:C000657245 |
355 | 318-326 | Species | denotes | patients | Tax:9606 |
353 | 392-395 | Gene | denotes | CRP | Gene:1401 |
356 | 457-465 | Species | denotes | patients | Tax:9606 |
357 | 475-484 | Species | denotes | SARS-CoV2 | Tax:2697049 |
358 | 547-556 | Species | denotes | SARS-CoV2 | Tax:2697049 |
LitCovid-sample-UniProt
Id | Subject | Object | Predicate | Lexical cue | uniprot_id |
---|---|---|---|---|---|
T1222 | 392-395 | Protein | denotes | CRP | https://www.uniprot.org/uniprot/Q5U0J2|https://www.uniprot.org/uniprot/Q07203|https://www.uniprot.org/uniprot/Q01687|https://www.uniprot.org/uniprot/P97315|https://www.uniprot.org/uniprot/P67967|https://www.uniprot.org/uniprot/P67966|https://www.uniprot.org/uniprot/P47875|https://www.uniprot.org/uniprot/P32965|https://www.uniprot.org/uniprot/P21291|https://www.uniprot.org/uniprot/P08462|https://www.uniprot.org/uniprot/A8K268 |
LitCovid-sample-Enju
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T94687 | 0-1 | DT | denotes | A |
T22655 | 2-7 | NN | denotes | pilot |
T19573 | 8-13 | NN | denotes | study |
T23972 | 14-15 | -LRB- | denotes | [ |
T55337 | 15-17 | CD | denotes | 11 |
T96728 | 17-18 | -RRB- | denotes | ] |
T92410 | 19-27 | RB | denotes | recently |
T26265 | 28-31 | VBZ | denotes | has |
T35997 | 32-44 | VBN | denotes | investigated |
T92380 | 45-48 | DT | denotes | the |
T38590 | 49-55 | NN | denotes | safety |
T37156 | 56-59 | CC | denotes | and |
T24661 | 60-66 | NN | denotes | effect |
T94632 | 67-69 | IN | denotes | of |
T56352 | 70-82 | JJ | denotes | convalescent |
T65134 | 83-89 | NN | denotes | plasma |
T64844 | 90-94 | WDT | denotes | that |
T95987 | 95-102 | VBP | denotes | contain |
T86655 | 103-111 | NN | denotes | antibody |
T45118 | 112-118 | NNS | denotes | levels |
T26321 | 119-125 | JJR | denotes | higher |
T17226 | 126-130 | IN | denotes | than |
T2522 | 131-132 | CD | denotes | 1 |
T48589 | 132-133 | -COLON- | denotes | : |
T90182 | 133-136 | CD | denotes | 640 |
T89317 | 137-145 | VBN | denotes | combined |
T28925 | 146-150 | IN | denotes | with |
T68950 | 151-158 | JJ | denotes | regular |
T58621 | 159-169 | JJ | denotes | anti-viral |
T22929 | 170-176 | NNS | denotes | agents |
T50644 | 177-180 | CC | denotes | and |
T63224 | 181-189 | JJ | denotes | standard |
T22041 | 190-200 | JJ | denotes | supportive |
T89053 | 201-205 | NN | denotes | care |
T94835 | 206-208 | IN | denotes | on |
T20257 | 209-217 | JJ | denotes | clinical |
T49329 | 218-226 | NNS | denotes | outcomes |
T91601 | 227-229 | IN | denotes | of |
T6238 | 230-233 | CD | denotes | ten |
T3048 | 234-242 | NNS | denotes | patients |
T18696 | 243-247 | IN | denotes | with |
T93206 | 248-254 | JJ | denotes | severe |
T71443 | 255-263 | NN | denotes | COVID-19 |
T46997 | 265-268 | DT | denotes | The |
T7672 | 269-274 | NN | denotes | study |
T83098 | 275-281 | VBD | denotes | showed |
T5017 | 282-290 | JJ | denotes | clinical |
T96870 | 291-302 | NN | denotes | improvement |
T42442 | 303-305 | IN | denotes | of |
T61149 | 306-309 | PDT | denotes | all |
T89276 | 310-313 | DT | denotes | the |
T53728 | 314-317 | CD | denotes | ten |
T50396 | 318-326 | NNS | denotes | patients |
T59179 | 327-338 | VBN | denotes | accompanied |
T83510 | 339-341 | IN | denotes | by |
T2183 | 342-344 | DT | denotes | an |
T4240 | 345-353 | NN | denotes | increase |
T18383 | 354-356 | IN | denotes | in |
T99269 | 357-367 | NN | denotes | lymphocyte |
T12131 | 368-373 | NN | denotes | count |
T36613 | 374-377 | CC | denotes | and |
T91622 | 378-379 | DT | denotes | a |
T39579 | 380-388 | NN | denotes | decrease |
T72559 | 389-391 | IN | denotes | in |
T31686 | 392-395 | NN | denotes | CRP |
T20580 | 397-406 | VBG | denotes | Following |
T23341 | 407-418 | NN | denotes | transfusion |
T23846 | 419-421 | IN | denotes | of |
T23496 | 422-434 | JJ | denotes | convalescent |
T68740 | 435-441 | NN | denotes | plasma |
T74721 | 441-442 | -COMMA- | denotes | , |
T3255 | 443-446 | PDT | denotes | all |
T47829 | 447-450 | DT | denotes | the |
T16466 | 451-456 | CD | denotes | seven |
T26913 | 457-465 | NNS | denotes | patients |
T47643 | 466-469 | WP | denotes | who |
T10299 | 470-474 | VBD | denotes | were |
T19318 | 475-484 | NN | denotes | SARS-CoV2 |
T2642 | 485-488 | NN | denotes | RNA |
T76428 | 489-497 | JJ | denotes | positive |
T59448 | 498-504 | IN | denotes | before |
T49967 | 505-516 | NN | denotes | transfusion |
T2352 | 517-519 | IN | denotes | of |
T3020 | 520-532 | JJ | denotes | convalescent |
T57517 | 533-539 | NN | denotes | plasma |
T55829 | 540-546 | VBD | denotes | turned |
T39392 | 547-556 | NN | denotes | SARS-CoV2 |
T26456 | 557-565 | JJ | denotes | negative |
T52249 | 567-572 | EX | denotes | There |
T13795 | 573-577 | VBD | denotes | were |
T15563 | 578-580 | DT | denotes | no |
T53693 | 581-588 | NN | denotes | control |
T35357 | 589-595 | NNS | denotes | groups |
T16756 | 596-605 | VBG | denotes | receiving |
T53621 | 606-618 | JJ | denotes | convalescent |
T81904 | 619-625 | NN | denotes | plasma |
T11852 | 626-631 | RB | denotes | alone |
T58859 | 632-634 | CC | denotes | or |
T35171 | 635-643 | JJ | denotes | standard |
T39367 | 644-651 | NN | denotes | therapy |
T20306 | 652-659 | IN | denotes | without |
T63670 | 660-672 | JJ | denotes | convalescent |
T44856 | 673-680 | NN | denotes | therapy |
T15733 | 681-683 | TO | denotes | to |
T71428 | 684-692 | VB | denotes | evaluate |
T29390 | 693-696 | DT | denotes | the |
T54708 | 697-701 | JJ | denotes | main |
T64138 | 702-708 | NN | denotes | effect |
T21425 | 709-711 | IN | denotes | of |
T75685 | 712-724 | JJ | denotes | convalescent |
T78861 | 725-731 | NN | denotes | plasma |
R32394 | T22929 | T58621 | arg1Of | agents,anti-viral |
R12539 | T22929 | T50644 | arg1Of | agents,and |
R32883 | T89053 | T50644 | arg2Of | care,and |
R99734 | T89053 | T63224 | arg1Of | care,standard |
R84751 | T89053 | T22041 | arg1Of | care,supportive |
R58957 | T48589 | T94835 | arg1Of | :,on |
R75573 | T49329 | T94835 | arg2Of | outcomes,on |
R52082 | T19573 | T94687 | arg1Of | study,A |
R65194 | T19573 | T22655 | arg1Of | study,pilot |
R95106 | T19573 | T23972 | arg1Of | study,[ |
R42168 | T55337 | T23972 | arg2Of | 11,[ |
R95339 | T96728 | T23972 | arg3Of | ],[ |
R78448 | T35997 | T92410 | arg1Of | investigated,recently |
R65706 | T19573 | T26265 | arg1Of | study,has |
R73941 | T35997 | T26265 | arg2Of | investigated,has |
R20951 | T19573 | T35997 | arg1Of | study,investigated |
R83087 | T37156 | T35997 | arg2Of | and,investigated |
R97536 | T37156 | T92380 | arg1Of | and,the |
R32731 | T38590 | T37156 | arg1Of | safety,and |
R69272 | T24661 | T37156 | arg2Of | effect,and |
R40627 | T37156 | T94632 | arg1Of | and,of |
R73729 | T65134 | T94632 | arg2Of | plasma,of |
R7895 | T65134 | T56352 | arg1Of | plasma,convalescent |
R7377 | T37156 | T64844 | arg1Of | and,that |
R67249 | T37156 | T95987 | arg1Of | and,contain |
R70225 | T45118 | T95987 | arg2Of | levels,contain |
R10830 | T45118 | T86655 | arg1Of | levels,antibody |
R61261 | T45118 | T26321 | arg1Of | levels,higher |
R50969 | T26321 | T17226 | arg1Of | higher,than |
R4008 | T48589 | T17226 | arg2Of | :,than |
R30054 | T2522 | T48589 | arg1Of | 1,: |
R45762 | T90182 | T48589 | arg2Of | 640,: |
R9970 | T48589 | T89317 | arg2Of | :,combined |
R87348 | T89317 | T28925 | arg1Of | combined,with |
R60332 | T50644 | T28925 | arg2Of | and,with |
R69387 | T22929 | T68950 | arg1Of | agents,regular |
R98484 | T49329 | T20257 | arg1Of | outcomes,clinical |
R34116 | T49329 | T91601 | arg1Of | outcomes,of |
R5522 | T3048 | T91601 | arg2Of | patients,of |
R74118 | T3048 | T6238 | arg1Of | patients,ten |
R51409 | T3048 | T18696 | arg1Of | patients,with |
R40479 | T71443 | T18696 | arg2Of | COVID-19,with |
R90019 | T71443 | T93206 | arg1Of | COVID-19,severe |
R55615 | T7672 | T46997 | arg1Of | study,The |
R40867 | T7672 | T83098 | arg1Of | study,showed |
R64658 | T96870 | T83098 | arg2Of | improvement,showed |
R66056 | T96870 | T5017 | arg1Of | improvement,clinical |
R52864 | T96870 | T42442 | arg1Of | improvement,of |
R70060 | T50396 | T42442 | arg2Of | patients,of |
R51479 | T50396 | T61149 | arg1Of | patients,all |
R50628 | T50396 | T89276 | arg1Of | patients,the |
R30895 | T50396 | T53728 | arg1Of | patients,ten |
R56320 | T36613 | T59179 | arg1Of | and,accompanied |
R2541 | T50396 | T59179 | arg2Of | patients,accompanied |
R80186 | T36613 | T83510 | arg2Of | and,by |
R38806 | T4240 | T2183 | arg1Of | increase,an |
R9880 | T4240 | T18383 | arg1Of | increase,in |
R77420 | T12131 | T18383 | arg2Of | count,in |
R60391 | T12131 | T99269 | arg1Of | count,lymphocyte |
R95922 | T4240 | T36613 | arg1Of | increase,and |
R85485 | T39579 | T36613 | arg2Of | decrease,and |
R67798 | T39579 | T91622 | arg1Of | decrease,a |
R82541 | T39579 | T72559 | arg1Of | decrease,in |
R48725 | T31686 | T72559 | arg2Of | CRP,in |
R83808 | T55829 | T20580 | arg1Of | turned,Following |
R25087 | T23341 | T20580 | arg2Of | transfusion,Following |
R66336 | T23341 | T23846 | arg1Of | transfusion,of |
R9016 | T68740 | T23846 | arg2Of | plasma,of |
R27767 | T68740 | T23496 | arg1Of | plasma,convalescent |
R79010 | T55829 | T74721 | arg1Of | turned,"," |
R49789 | T26913 | T3255 | arg1Of | patients,all |
R98083 | T26913 | T47829 | arg1Of | patients,the |
R36266 | T26913 | T16466 | arg1Of | patients,seven |
R42101 | T26913 | T47643 | arg1Of | patients,who |
R24725 | T26913 | T10299 | arg1Of | patients,were |
R12375 | T2642 | T10299 | arg2Of | RNA,were |
R19448 | T2642 | T19318 | arg1Of | RNA,SARS-CoV2 |
R23710 | T2642 | T76428 | arg1Of | RNA,positive |
R34529 | T10299 | T59448 | arg1Of | were,before |
R60141 | T49967 | T59448 | arg2Of | transfusion,before |
R2931 | T49967 | T2352 | arg1Of | transfusion,of |
R3822 | T57517 | T2352 | arg2Of | plasma,of |
R20207 | T57517 | T3020 | arg1Of | plasma,convalescent |
R30096 | T26913 | T55829 | arg1Of | patients,turned |
R66579 | T26456 | T55829 | arg2Of | negative,turned |
R14919 | T26456 | T39392 | arg1Of | negative,SARS-CoV2 |
R49718 | T26913 | T26456 | arg1Of | patients,negative |
R70070 | T52249 | T13795 | arg1Of | There,were |
R68506 | T35357 | T13795 | arg2Of | groups,were |
R94657 | T35357 | T15563 | arg1Of | groups,no |
R49835 | T35357 | T53693 | arg1Of | groups,control |
R88768 | T35357 | T16756 | arg1Of | groups,receiving |
R7103 | T58859 | T16756 | arg2Of | or,receiving |
R65241 | T81904 | T53621 | arg1Of | plasma,convalescent |
R80896 | T81904 | T11852 | arg1Of | plasma,alone |
R48507 | T81904 | T58859 | arg1Of | plasma,or |
R74990 | T39367 | T58859 | arg2Of | therapy,or |
R57531 | T39367 | T35171 | arg1Of | therapy,standard |
R26123 | T16756 | T20306 | arg1Of | receiving,without |
R11811 | T44856 | T20306 | arg2Of | therapy,without |
R59105 | T44856 | T63670 | arg1Of | therapy,convalescent |
R40530 | T71428 | T15733 | arg1Of | evaluate,to |
R29016 | T16756 | T15733 | modOf | receiving,to |
R33735 | T64138 | T71428 | arg2Of | effect,evaluate |
R2474 | T64138 | T29390 | arg1Of | effect,the |
R56840 | T64138 | T54708 | arg1Of | effect,main |
R22469 | T64138 | T21425 | arg1Of | effect,of |
R7749 | T78861 | T21425 | arg2Of | plasma,of |
R22133 | T78861 | T75685 | arg1Of | plasma,convalescent |
LitCovid-sample-PD-FMA
Id | Subject | Object | Predicate | Lexical cue | fma_id |
---|---|---|---|---|---|
T75 | 83-89 | Body_part | denotes | plasma | http://purl.org/sig/ont/fma/fma62970 |
T76 | 103-111 | Body_part | denotes | antibody | http://purl.org/sig/ont/fma/fma62871 |
T77 | 357-367 | Body_part | denotes | lymphocyte | http://purl.org/sig/ont/fma/fma62863 |
T78 | 435-441 | Body_part | denotes | plasma | http://purl.org/sig/ont/fma/fma62970 |
T79 | 485-488 | Body_part | denotes | RNA | http://purl.org/sig/ont/fma/fma67095 |
T80 | 533-539 | Body_part | denotes | plasma | http://purl.org/sig/ont/fma/fma62970 |
T81 | 619-625 | Body_part | denotes | plasma | http://purl.org/sig/ont/fma/fma62970 |
T82 | 725-731 | Body_part | denotes | plasma | http://purl.org/sig/ont/fma/fma62970 |
LitCovid-sample-PD-MONDO
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T64 | 255-263 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T65 | 475-484 | Disease | denotes | SARS-CoV2 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T66 | 547-556 | Disease | denotes | SARS-CoV2 | http://purl.obolibrary.org/obo/MONDO_0100096 |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T92 | 0-264 | Sentence | denotes | A pilot study [11] recently has investigated the safety and effect of convalescent plasma that contain antibody levels higher than 1:640 combined with regular anti-viral agents and standard supportive care on clinical outcomes of ten patients with severe COVID-19. |
T93 | 265-396 | Sentence | denotes | The study showed clinical improvement of all the ten patients accompanied by an increase in lymphocyte count and a decrease in CRP. |
T94 | 397-566 | Sentence | denotes | Following transfusion of convalescent plasma, all the seven patients who were SARS-CoV2 RNA positive before transfusion of convalescent plasma turned SARS-CoV2 negative. |
T95 | 567-732 | Sentence | denotes | There were no control groups receiving convalescent plasma alone or standard therapy without convalescent therapy to evaluate the main effect of convalescent plasma. |